Skip to content

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›Perspective Therapeutics, Inc. (CATX)

Perspective Therapeutics, Inc.

CATX

Held by 1 specialist biotech fund

High short interest · No specialist buying

1 fund opened new positions. Short interest: 14.3% of float.

Share

Score Holdings Short Interest Catalysts Insiders Research

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

CATX: Held by 1 Biotech Hedge Fund (2026) | BiotechEdge

Signal Score

1.5/10

1 fund opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 1 specialist fund●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Commodore CapitalNew

AI Signal

Commodore Capital (Atkinson & Kramarz), a dedicated healthcare specialist, initiated a 6.34M-share position (~$26.4M) in Perspective Therapeutics (CATX), a clinical-stage company developing targeted alpha therapy (TAT) with lead asset VMT-α-NET in somatostatin receptor-positive neuroendocrine tumors, alongside an ocular melanoma franchise (131I-CLR1404). The initiation size is meaningful relative to Commodore's typical position construction and suggests conviction ahead of anticipated clinical readouts and potential NDA-related catalysts for their lead programs. Investors should monitor CATX's cash runway closely, as TAT development is capital-intensive and a position of this scale by a specialist fund may precede a structured financing or partnership event that could introduce dilution risk.

Unlock full AI analysis — 14-day free trial

Short Interest

High short interest

Short Shares

13.63M

Change

+8.1%

Days to Cover

10.3

% of Float

14.3%

Settlement

Jun 15, 2026

Short interest over 9 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13GCommodore Capital9.9%Feb 9, 2026

SC 13G/ACommodore Capital5.0%Nov 14, 2024

SC 13GCommodore Capital6.6%Apr 19, 2024

Position Details

Commodore CapitalNEW POSITIONMay 15, 2026

Start free trialfor share counts, dollar values & AI analysis

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

AAVXF1 fund ALKS1 fund APGE1 fund ARVN1 fund AVTX1 fund ACET1 fund AUTL1 fund CCCC1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: